Melum E, Karlsen T H, Broomé U, Thorsby E, Schrumpf E, Boberg K M, Lie B A
Institute of Immunology, Rikshospitalet University Hospital, Sognsvannsyn 20, 0027 Oslo, Norway.
Tissue Antigens. 2006 Jul;68(1):78-81. doi: 10.1111/j.1399-0039.2006.00604.x.
CCR5 is a chemokine receptor expressed on T-cells and macrophages. A 32-base pair deletion in the chemokine receptor 5 gene (CCR5-Delta32) leads to a non-functional receptor. Conflicting evidence exists whether this deletion is associated with primary sclerosing cholangitis (PSC). We genotyped the CCR5-Delta32 variant in 363 PSC patients and 366 controls. No significant increase in the Delta32 allele frequency was detected in the PSC patients compared to controls (12.7% vs 10.7% OR = 1.22, 95% CI [0.88, 1.68], P = 0.23). Survival analysis did not reveal any significant effects from CCR5-Delta32 genotypes on disease progression. Thus, in this study (power > 90%, given OR = 2, alpha = 0.05), we were unable to replicate previous findings and our results do not support an involvement of CCR5-Delta32 in either PSC susceptibility or progression.
CCR5是一种在T细胞和巨噬细胞上表达的趋化因子受体。趋化因子受体5基因(CCR5-Δ32)中的32个碱基对缺失导致受体功能丧失。关于这种缺失是否与原发性硬化性胆管炎(PSC)相关,存在相互矛盾的证据。我们对363例PSC患者和366例对照进行了CCR5-Δ32变体的基因分型。与对照组相比,在PSC患者中未检测到Δ32等位基因频率有显著增加(12.7%对10.7%,OR = 1.22,95%可信区间[0.88, 1.68],P = 0.23)。生存分析未发现CCR5-Δ32基因型对疾病进展有任何显著影响。因此,在本研究中(效能>90%,给定OR = 2,α = 0.05),我们无法重复先前的发现,且我们的结果不支持CCR5-Δ32参与PSC易感性或疾病进展。